Cardiac Protection for Noncardiac Surgery

  • P. Foëx
  • G. Howard-Alpe
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)


Cardiovascular complications of anesthesia and surgery remain, unfortunately, very frequent. In the USA, Mangano and Goldman concluded that approximately 27 million anesthetics were given every year, including 8 million to patients with coronary artery disease. They estimated the number of cardiovascular complications to be approximately 1 million per annum, including 500 000 postoperative myocardial infarctions [1]. This represents one cardiovascular complication for every 27 anesthetics. The complications considered in this context include myocardial infarction, unstable angina, life-threatening arrhythmias, and acute left ventricular failure.


Myocardial Ischemia Noncardiac Surgery Cardiac Protection Postoperative Myocardial Infarction Adverse Cardiac Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mangano DT (1995) Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? Anesthesiology 83:897–901PubMedCrossRefGoogle Scholar
  2. 2.
    National Confidential Enquiry into Perioperative Deaths (1999) Extremes of age. The 1999 Report of the National Confidential Enquiry into Perioperative Deaths. The National Confidential Enquiry into Perioperative DeathsGoogle Scholar
  3. 3.
    National Confidential Enquiry into Perioperative Deaths (2001) Then and now: the 2000 report of the National Confidential Enquiry into Postoperative Deaths. The National Confidential Enquiry into Postoperative DeathsGoogle Scholar
  4. 4.
    Devereaux PJ, Beattie WS, Choi PT et al (2005) How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 331:313–321PubMedCrossRefGoogle Scholar
  5. 5.
    Mangano DT, Browner WS, Hollenberg M et al (1992) Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 268:233–239PubMedCrossRefGoogle Scholar
  6. 6.
    Mangano DT (1998) Adverse outcomes after surgery in the year 2001-a continuing odyssey. Anesthesiology 88:561–564PubMedCrossRefGoogle Scholar
  7. 7.
    Poldermans D, Boersma E, Bax JJ et al (1999) The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 341:1789–1794PubMedCrossRefGoogle Scholar
  8. 8.
    Mamode N, Docherty G, Lowe GD et al (2001) The role of myocardial perfusion scanning, heart rate variability and d-dimers in predicting the risk of perioperative cardiac complications after peripheral vascular surgery. Eur J Vasc Endovasc Surg 22:499–508PubMedCrossRefGoogle Scholar
  9. 9.
    Beattie MS, Shlipak MG, Liu H et al (2003) C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation 107:245–250PubMedCrossRefGoogle Scholar
  10. 10.
    Blake GJ, Ridker PM (2003) C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41(4 Suppl S):37S–42SPubMedCrossRefGoogle Scholar
  11. 11.
    Eagle KA, Berger PB, Calkins H et al (2002) ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery. Circulation 105:1257–1267PubMedGoogle Scholar
  12. 12.
    McFalls EO, Ward HB, Moritz TE et al (2004) Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351:2795–2804PubMedCrossRefGoogle Scholar
  13. 13.
    Posner KL, Van Norman GA, Chan V (1999) Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Anesth Analg 89:553–560PubMedCrossRefGoogle Scholar
  14. 14.
    Godet G, Riou B, Bertrand M et al (2005) Does preoperative coronary angioplasty improve perioperative cardiac outcome? Anesthesiology 102:739–746PubMedCrossRefGoogle Scholar
  15. 15.
    Grayburn PA, Hillis LD (2003) Cardiac events in patients undergoing noncardiac surgery: shifting the paradigm from noninvasive risk stratification to therapy. Ann Intern Med 138:506–511PubMedGoogle Scholar
  16. 16.
    Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesth Analg 2003;97:623–633PubMedCrossRefGoogle Scholar
  17. 17.
    Sear JW, Howell SJ, Sear YM et al (2001) Intercurrent drug therapy and perioperative cardiovascular mortality in elective and urgent/emergency surgical patients. Br J Anaesth 86:506–512PubMedCrossRefGoogle Scholar
  18. 18.
    Nishina K, Mikawa K, Uesugi T et al (2002) Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 96:323–329PubMedCrossRefGoogle Scholar
  19. 19.
    Wallace AW, Galindez D, Salahieh A et al (2004) Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 101:284–293PubMedCrossRefGoogle Scholar
  20. 20.
    Oliver MF, Goldman L, Julian DG, Holme I (1999) Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 91:951–961PubMedCrossRefGoogle Scholar
  21. 21.
    Mangano DT (1997) Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. JAMA 277:325–332PubMedCrossRefGoogle Scholar
  22. 22.
    Kaneko T, Saito Y, Hikawa Y et al (2001) Dose-dependent prophylactic effect of nicorandil, an ATP-sensitive potassium channel opener, on intra-operative myocardial ischaemia in patients undergoing major abdominal surgery. Br J Anaesth 86:332–337PubMedCrossRefGoogle Scholar
  23. 23.
    Teshima Y, Akao M, Jones SP et al (2003) Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway. Circulation 108:2275–2281PubMedCrossRefGoogle Scholar
  24. 24.
    Rungwerth K, Schindler U, Gerl M et al (2004) Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. Br J Pharmacol 142:1147–1154PubMedCrossRefGoogle Scholar
  25. 25.
    Xu Z, Jiao Z, Cohen MV, Downey JM (2002) Protection from AMP 579 can be added to that from either cariporide or ischemic preconditioning in ischemic rabbit heart. J Cardiovasc Pharmacol 40:510–518PubMedCrossRefGoogle Scholar
  26. 26.
    Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153PubMedCrossRefGoogle Scholar
  27. 27.
    Kertai MD, Boersma E, Westerhout CM et al (2004) Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med 116:96–103PubMedCrossRefGoogle Scholar
  28. 28.
    Ohtsuka T, Hamada M, Hiasa G et al (2001) Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37:412–417PubMedCrossRefGoogle Scholar
  29. 29.
    Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 349:1391–1393PubMedCrossRefGoogle Scholar
  30. 30.
    ISIS-1 (1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2:57–66Google Scholar
  31. 31.
    Owen A (1998) Intravenous beta blockade in acute myocardial infarction. Should be used in combination with thrombolysis. BMJ 317:226–227PubMedGoogle Scholar
  32. 32.
    Pepine CJ, Cohn PF, Deedwania PC et al (1994) Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 90:762–768PubMedGoogle Scholar
  33. 33.
    Carlberg B, Samuelsson O, Lindholm LH (2004) Atenolol in hypertension: is it a wise choice? Lancet 364:1684–1689PubMedCrossRefGoogle Scholar
  34. 34.
    Dahlof B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 366:895–906PubMedCrossRefGoogle Scholar
  35. 35.
    Poulter NR, Wedel H, Dahlof B et al (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366:907–913PubMedCrossRefGoogle Scholar
  36. 36.
    Prys-Roberts C, Foex P, Biro GP, Roberts JG (1973) Studies of anaesthesia in relation to hypertension. V. Adrenergic beta-receptor blockade. Br J Anaesth 45:671–681PubMedCrossRefGoogle Scholar
  37. 37.
    Stone JG, Foex P, Sear JW et al (1988) Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology 68:495–500PubMedGoogle Scholar
  38. 38.
    Wallace A, Layug B, Tateo I et al (1988) Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 88:7–17CrossRefGoogle Scholar
  39. 39.
    Pasternack PF, Imparato AM, Baumann FG et al (1987) The hemodynamics of beta-blockade in patients undergoing abdominal aortic aneurysm repair. Circulation 76(3 Pt 2):III1–7PubMedGoogle Scholar
  40. 40.
    Yeager RA, Moneta GL, Edwards JM et al (1995) Reducing perioperative myocardial infarction following vascular surgery. The potential role of beta-blockade. Arch Surg 130:869–872; discussion 72–73PubMedGoogle Scholar
  41. 41.
    Mangano DT, Layug EL, Wallace A, Tateo I (1996) Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 335:1713–1720PubMedCrossRefGoogle Scholar
  42. 42.
    Palda VA, Detsky AS (1997) Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 127:313–328PubMedGoogle Scholar
  43. 43.
    Roizen MF (1988) Should we all have a sympathectomy at birth? Or at least preoperatively? Anesthesiology 68:482–484PubMedCrossRefGoogle Scholar
  44. 44.
    Auerbach AD, Goldman L (2002) beta-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 287:1435–1444PubMedCrossRefGoogle Scholar
  45. 45.
    Schouten O, Shaw LJ, Boersma E et al (2006) A meta-analysis of safety and effectiveness of perioperative beta-blocker use for the prevention of cardiac events in different types of noncardiac surgery. Coron Artery Dis 17:173–179PubMedCrossRefGoogle Scholar
  46. 46.
    Taylor RC, Pagliarello G (2003) Prophylactic beta-blockade to prevent myocardial infarction perioperatively in high-risk patients who undergo general surgical procedures. Can J Surg 46:216–222PubMedGoogle Scholar
  47. 47.
    Rapchuk I, Rabuka S, Tonelli M (2004) Perioperative use of beta-blockers remains low: experience of a single Canadian tertiary institution. Can J Anaesth 51:761–767PubMedGoogle Scholar
  48. 48.
    POISE Trial Investigators, Devereaux PJ, Yang H, Guyatt GH et al (2006) Rationale, design, and organization of the PeriOperative ISchemic Evalutaion (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. Am Heart J S2:223–230Google Scholar
  49. 49.
    Devereaux PJ, Leslie K (2004) Best evidence in anesthetic practice. Prevention: alpha2-and beta-adrenergic antagonists reduce perioperative cardiac events. Can J Anaesth 51:290–292PubMedCrossRefGoogle Scholar
  50. 50.
    Devereaux PJ, Yusuf S, Yang H et al (2004) Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? Can Med Assoc J 171:245–247CrossRefGoogle Scholar
  51. 51.
    ten Broecke PW, De Hert SG, Mertens E, Adriaensen HF (2003) Effect of preoperative beta-blockade on perioperative mortality in coronary surgery. Br J Anaesth 90:27–31PubMedCrossRefGoogle Scholar
  52. 52.
    Giles JW, Sear JW, Foex P (2004) Effect of chronic beta-blockade on peri-operative outcome in patients undergoing non-cardiac surgery: an analysis of observational and case control studies. Anaesthesia 59:574–583PubMedCrossRefGoogle Scholar
  53. 53.
    Yndgaard S, Lippert FK, Berthelsen PG (1997) Are patients chronically treated with beta 1-adrenoceptor antagonists in fact beta-blocked? J Cardiothorac Vasc Anesth 11:32–36PubMedCrossRefGoogle Scholar
  54. 54.
    Tzivoni D, Medina A, David D et al (1998) Effect of metoprolol in reducing myocardial ischemic threshold during exercise and during daily activity. Am J Cardiol 81:775–777PubMedCrossRefGoogle Scholar
  55. 55.
    Raby KE, Brull SJ, Timimi F et al (1999) The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 88:477–482PubMedCrossRefGoogle Scholar
  56. 56.
    Juul AB, Wetterslev J, Kofoed Enevoldsen A et al (2004) The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery. Am Heart J 147:677–683PubMedCrossRefGoogle Scholar
  57. 57.
    Shammash JB, Trost JC, Gold JM et al (2001) Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 141:148–153PubMedCrossRefGoogle Scholar
  58. 58.
    Yang H, Raymer K, Butler R et al (2004) Metoprolol after vascular surgery (MaVS). Can J Anaesth 51:A7Google Scholar
  59. 59.
    Brady AR, Gibbs JS, Greenhalgh RM et al (2005) Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg 41:602–609PubMedCrossRefGoogle Scholar
  60. 60.
    Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489–497PubMedCrossRefGoogle Scholar
  61. 61.
    Naghavi M, Libby P, Falk E et al From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772–8PubMedCrossRefGoogle Scholar
  62. 62.
    Willerson JT, Ridker PM (2003) Inflammation as a cardiovascular risk factor. Circulation 109[21 Suppl 1]:II2–10Google Scholar
  63. 63.
    Poldermans D, Bax JJ, Kertai MD et al (2003) Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 107:1848–1851PubMedCrossRefGoogle Scholar
  64. 64.
    Lindenauer PK, Pekow P, Wang K et al (2004) Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291:2092–2099PubMedCrossRefGoogle Scholar
  65. 65.
    O’Neil-Callahan K, Katsimaglis G, Tepper MR et al (2005) Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 45:336–342PubMedCrossRefGoogle Scholar
  66. 66.
    Ward RP, Leeper NJ, Kirkpatrick JN et al (2005) The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 104:264–268PubMedCrossRefGoogle Scholar
  67. 67.
    Ali IS, Buth KJ (2005) Preoperative statin use and outcomes following cardiac surgery. Int J Cardiol 103:12–18PubMedCrossRefGoogle Scholar
  68. 68.
    Durazzo AE, Machado FS, Ikeoka DT et al (2004) Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 39:967–975PubMedCrossRefGoogle Scholar
  69. 69.
    Schouten O, Kertai MD, Bax JJ et al Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 95:658–660Google Scholar
  70. 70.
    Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539–540PubMedCrossRefGoogle Scholar
  71. 71.
    Shepherd J, Hunninghake DB, Stein EA et al (2004) Safety of rosuvastatin. Am J Cardiol 94:882–888PubMedCrossRefGoogle Scholar
  72. 72.
    Heeschen C, Hamm CW, Laufs U et al Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446–52PubMedCrossRefGoogle Scholar
  73. 73.
    Chan AW, Bhatt DL, Chew DP et al (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105:691–696PubMedCrossRefGoogle Scholar
  74. 74.
    Mangano DT (2002) Aspirin and mortality from coronary bypass surgery. N Engl J Med 347:1309–1317PubMedCrossRefGoogle Scholar
  75. 75.
    Lim E, Ali Z, Ali A et al (2003) Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 327:1309PubMedCrossRefGoogle Scholar
  76. 76.
    Rodgers A et al (2000) The Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355: 1295–1302CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • P. Foëx
    • 1
  • G. Howard-Alpe
    • 1
  1. 1.Nuffield Department of AnaestheticsUniversity of OxfordOxfordUK

Personalised recommendations